The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Bleximenib combined with venetoclax and azacitidine in R/R AML with KMT2A or NPM1 alterations
Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, discusses a study on the menin inhibitor bleximenib combined with venetoclax and azacitidine in relapsed/refractory (R/R) acute myeloid leukemia (AML) with KMT2A or NPM1 alterations. The study reported no increased toxicities compared to venetoclax and azacitidine alone, an overall response rate (ORR) of 79%, and a composite complete remission (CRc) rate of 41%. There was a 65% response rate in patients with prior venetoclax exposure. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
